During the early 2000s, the word “gay” floated through casual speech like punctuation: a throwaway adjective that collapsed ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion Pharmaceuticals, Inc ( ($RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc ...

Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...